Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
Tshepiso Madihlaba, Kim Papp, Andrew J.K. Östör, Michael M. Chen et al.
Citations
1 citations
Journal
Rheumatology and Therapy
Topics
Spondyloarthritis Studies and Treatments
Field-Weighted Citation Impact (FWCI)
1.67
article
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
Tshepiso Madihlaba, Kim Papp, Andrew J.K. Östör, Michael M. Chen, Kyle Carter, Douglas White, Filip Van den Bosch, A Crowley, Fang Liu, Lila Glotfelty, Ana Biljan, Alan Kivitz, Ricardo Blanco, Ahmed M. Soliman, Mauro Waldemar Keiserman, Doug Ashley
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Rheumatology and TherapyVol. 12(6)
Institutions
Australian National University (AU), University of Auckland (NZ), University of Toronto (CA), Ghent University Hospital (BE), Waikato Hospital (NZ), AbbVie (United States) (US), Cabrini Hospital (AU), Altoona Center for Clinical Research (US), Instituto de Investigación Marqués de Valdecilla (ES), Willow Wood (United States) (US), Probity Medical Research (CA), Mental Illness Fellowship (AU), VIB-UGent Center for Inflammation Research (BE), Digital Research Alliance of Canada, Pontifícia Universidade Católica do Rio Grande do Sul (BR), Monash University (AU), RMIT University (AU)